EGFR and breast carcinoma: As shown in Fig. 5c, we engineered EGFR and Her2/neu reactive hemibodies and an EGFR-specific BiTE control and tested their abilities to redirect T cells to the dual antigen-positive breast cancer cell line MDA-MB-231 (Fig. 5c).